WARNING: This product is for research use only, not for human or veterinary use.
MedKoo CAT#: 406801
Description: L-165041, also known as L-165,041, is a potent and selective agonist of the nuclear receptor PPARβ/δ (Ki = 9 nM, EC50 = ~500 nM for hPPARβ/δ). L-165041 promotes VEGF mRNA stabilization in HPV18-harboring HeLa cells through a receptor-independent mechanism. L-165041 inhibits VEGF-induced angiogenesis, but the antiangiogenic effect is not related to PPARδ. L-165041 inhibits rat vascular smooth muscle cell proliferation and migration via inhibition of cell cycle.
MedKoo Cat#: 406801
Chemical Formula: C22H26O7
Exact Mass: 402.1679
Molecular Weight: 402.443
Elemental Analysis: Elemental Analysis: C, 65.66; H, 6.51; O, 27.83
Synonym: L-165041; L165041; L 165041; L-165,041; L165,041; L 165,041.
IUPAC/Chemical Name: 2-[4-[3-(4-acetyl-3-hydroxy-2-propylphenoxy)propoxy]phenoxy]-acetic acid
InChi Key: HBBVCKCCQCQCTJ-UHFFFAOYSA-N
InChi Code: InChI=1S/C22H26O7/c1-3-5-19-20(11-10-18(15(2)23)22(19)26)28-13-4-12-27-16-6-8-17(9-7-16)29-14-21(24)25/h6-11,26H,3-5,12-14H2,1-2H3,(H,24,25)
SMILES Code: O=C(O)COC1=CC=C(OCCCOC2=CC=C(C(C)=O)C(O)=C2CCC)C=C1
Appearance: Solid powder
Purity: >98% (or refer to the Certificate of Analysis)
Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility: Soluble in DMSO
Shelf Life: >2 years if stored properly
Drug Formulation: This drug may be formulated in DMSO
Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code: 2934.99.9001
The following data is based on the product molecular weight 402.443 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.
|Concentration / Solvent Volume / Mass||1 mg||5 mg||10 mg|
|1 mM||1.15 mL||5.76 mL||11.51 mL|
|5 mM||0.23 mL||1.15 mL||2.3 mL|
|10 mM||0.12 mL||0.58 mL||1.15 mL|
|50 mM||0.02 mL||0.12 mL||0.23 mL|
1: Roche E, Lascombe I, Bittard H, Mougin C, Fauconnet S. The PPARβ agonist
L-165041 promotes VEGF mRNA stabilization in HPV18-harboring HeLa cells through a
receptor-independent mechanism. Cell Signal. 2014 Feb;26(2):433-43. doi:
10.1016/j.cellsig.2013.10.006. Epub 2013 Oct 28. PubMed PMID: 24172859.
2: Park JH, Lee KS, Lim HJ, Kim H, Kwak HJ, Park HY. The PPARδ ligand L-165041
inhibits VEGF-induced angiogenesis, but the antiangiogenic effect is not related
to PPARδ. J Cell Biochem. 2012 Jun;113(6):1947-54. doi: 10.1002/jcb.24063. PubMed
3: Lim HJ, Park JH, Lee S, Choi HE, Lee KS, Park HY. PPARdelta ligand L-165041
ameliorates Western diet-induced hepatic lipid accumulation and inflammation in
LDLR-/- mice. Eur J Pharmacol. 2009 Nov 10;622(1-3):45-51. doi:
10.1016/j.ejphar.2009.09.002. Epub 2009 Sep 18. PubMed PMID: 19766624.
4: Lim HJ, Lee S, Park JH, Lee KS, Choi HE, Chung KS, Lee HH, Park HY. PPAR delta
agonist L-165041 inhibits rat vascular smooth muscle cell proliferation and
migration via inhibition of cell cycle. Atherosclerosis. 2009 Feb;202(2):446-54.
doi: 10.1016/j.atherosclerosis.2008.05.023. Epub 2008 May 21. PubMed PMID: